Prospective Validation of the "rhino Conjunctivitis Allergy-control-SCORE©" (RC-ACS©)

Overview

Journal Clin Transl Allergy

Publisher Wiley

Specialty Allergy & Immunology

Date 2012 Sep 21

PMID 22992280

Authors

Dietrich Hafner

Kristian Reich

Ina Zschocke

Annett Lotzin

Hanns Meyer

Jens Kettner

Annemie Narkus

Affiliations

Soon will be listed here.

Abstract

Background: Recently we reported the validation of the "Allergy-Control-SCORE© (ACS)" which assesses symptom severity as well as medication use on three dimensions lung, nose and eyes. The aim of this study was to test the validity of the score for eyes and nose.

Methods: One-hundred-twenty-one consenting subjects (age 19-65y), including 81 patients with allergic rhino-conjunctivitis (RC) and 40 healthy controls, participated in the study. Patients rated daily nasal and eye symptoms using a 4-point scale (none, mild, moderate, and severe) and their use of anti-symptomatic medication. Validation criteria were pollen counts in the course of the study period. Discrimination capacity was analyzed by comparing the rhino-conjunctivitis Allergy-Control-SCORE© (RC-ACS©) values of allergic patients and healthy controls. Convergent reliability was assessed by correlating RC-ACS© values with the global severity of allergy, the quality of life, and the allergy-related medical consultations. Retest reliability was assessed by the correlation of the repeated measured RC-ACS© scores during each of two consecutive weeks.

Results: Convergent reliability analysis indicated a significant correlation between RC-Allergy-Control-SCORE© and global severity of allergy (r = 0.691; p < 0.0001), quality of life (r = 0.757; p < 0.0001) and allergy-related medical consultations (r = 0.329; p = 0.0019). RC-Allergy-Control-SCORE© showed a good retest reliability (r = 0.813; p < 0.001) and discriminated extremely well between allergic patients and healthy controls (Median: 3.7 range: 0; 14.1 vs. Median: 0 range: 0; 2.9; p < 0.001), with a sensitivity of 93.8% and a specificity of 92.5% at a score value of 0.786.

Conclusions: The RC-ACS© can be considered as valid and reliable to assess the severity of rhino-conjunctivitis severity in clinical trials and observational studies.

References

Bousquet P, Combescure C, Neukirch F, Klossek J, Mechin H, Daures J . Visual analog scales can assess the severity of rhinitis graded according to ARIA guidelines. Allergy. 2007; 62(4):367-72. DOI: 10.1111/j.1398-9995.2006.01276.x. View

Bousquet J, Khaltaev N, Cruz A, Denburg J, Fokkens W, Togias A . Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy. 2008; 63 Suppl 86:8-160. DOI: 10.1111/j.1398-9995.2007.01620.x. View

Corrigan C, Kettner J, Doemer C, Cromwell O, Narkus A . Efficacy and safety of preseasonal-specific immunotherapy with an aluminium-adsorbed six-grass pollen allergoid. Allergy. 2005; 60(6):801-7. DOI: 10.1111/j.1398-9995.2005.00790.x. View

Melioli G, Marcomini L, Agazzi A, Bazurro G, Tosca M, Rossi G . The IgE repertoire in children and adolescents resolved at component level: a cross-sectional study. Pediatr Allergy Immunol. 2011; 23(5):433-40. DOI: 10.1111/j.1399-3038.2011.01228.x. View

Klimek L, Mewes T, Wolf H, Hansen I, Schnitker J, Mann W . The effects of short-term immunotherapy using molecular standardized grass and rye allergens compared with symptomatic drug treatment on rhinoconjunctivitis symptoms, skin sensitivity, and specific nasal reactivity. Otolaryngol Head Neck Surg. 2005; 133(4):538-43. DOI: 10.1016/j.otohns.2005.07.020. View

Canonica G, Baena-Cagnani C, Bousquet J, Bousquet P, Lockey R, Malling H . Recommendations for standardization of clinical trials with Allergen Specific Immunotherapy for respiratory allergy. A statement of a World Allergy Organization (WAO) taskforce. Allergy. 2007; 62(3):317-24. DOI: 10.1111/j.1398-9995.2006.01312.x. View

Pfaar O, Kleine-Tebbe J, Hormann K, Klimek L . Allergen-specific immunotherapy: which outcome measures are useful in monitoring clinical trials?. Immunol Allergy Clin North Am. 2011; 31(2):289-309, x. DOI: 10.1016/j.iac.2011.02.004. View

Juniper E, Guyatt G . Development and testing of a new measure of health status for clinical trials in rhinoconjunctivitis. Clin Exp Allergy. 1991; 21(1):77-83. DOI: 10.1111/j.1365-2222.1991.tb00807.x. View

Clark J, Schall R . Assessment of combined symptom and medication scores for rhinoconjunctivitis immunotherapy clinical trials. Allergy. 2007; 62(9):1023-8. DOI: 10.1111/j.1398-9995.2007.01469.x. View

10.

Pfaar O, Klimek L . Efficacy and safety of specific immunotherapy with a high-dose sublingual grass pollen preparation: a double-blind, placebo-controlled trial. Ann Allergy Asthma Immunol. 2008; 100(3):256-63. DOI: 10.1016/s1081-1206(10)60451-6. View

11.

Hafner D, Reich K, Matricardi P, Meyer H, Kettner J, Narkus A . Prospective validation of 'Allergy-Control-SCORE(TM)': a novel symptom-medication score for clinical trials. Allergy. 2011; 66(5):629-36. DOI: 10.1111/j.1398-9995.2010.02531.x. View

12.

Baiardini I, Bousquet P, Brzoza Z, Canonica G, Compalati E, Fiocchi A . Recommendations for assessing patient-reported outcomes and health-related quality of life in clinical trials on allergy: a GA(2)LEN taskforce position paper. Allergy. 2009; 65(3):290-5. DOI: 10.1111/j.1398-9995.2009.02263.x. View